Cardiovascular Outcome Trials: Strategic Insights for Country and Site Distribution

Driving study completion in a cardiovascular outcome trial (CVOT) requires extensive planning from the onset to prevent costly errors from remediation, avoid prolonged enrollment periods and minimize delayed or reduced event occurrence. Drug development sponsors need to begin with the end in mind to capture the right endpoints, including targeted patient populations for labeling purposes and securing the trial includes patients who would most benefit from the study drug to ensure a potential market. To help drug development sponsors run an efficient CVOT, this white paper shares key operational considerations and describes the use of proprietary tools and processes combined with information in the public domain to support both country and site selection.